BioIVT Vice President of Marketing Courtney Noah, PhD, said the acquisition broadens BioIVT’s capabilities in the in vitro diagnostics (IVD) space “by providing expanded control products and Keystone Biologicals’ expertise in the collection of bulk units of disease-state and normal sera and plasma.”
Following the transaction – financial terms of which were not disclosed – Keystone Biologicals will become part of the BioIVT organization.
With the addition, BioIVT will provide ‘comprehensive’ solutions, including remnant biofluids and tissues for early drug development, clinical specimens and point-of-care services for validation studies, and disease-state plasma collected as bulk units to support IVD manufacturing requirements, said Noah.
“When it comes to diagnostic kit development and manufacturing, IVD researchers need a reliable source for control and calibrator plasma and sera,” she added.
Little change will be seen in the early phases of integration, though as the companies fully merge, Noah said, “we will be looking to drive operational efficiencies and customer service processes that will serve to enhance the client experience.”
BioIVT – formerly BioreclamationIVT – has made several acquisitions over the last couple years, and standardized its site processes to manage clinical trial data at all of its locations.